Sugi Predict

Sugi Predict / Targets / SPINT2

SPINT2

Kunitz-type protease inhibitor 2 · O43291 · SPINT2 on Sugi Atlas →

0 patent compounds predicted against SPINT2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to SPINT2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography PHASE4UNKNOWN
Telmisartan for Treatment of COVID-19 Patients PHASE4COMPLETED
Evaluation of Statin Mechanism Preventing Cardiovascular Disease by Post-hoc Analysis of Treating to New Targets Study PHASE4COMPLETED
Clinical Trial With Aprotinin in the Acute Respiratory Distress Syndrome Treatment PHASE3NOT_YET_RECRUITING
Bradykinin Receptor Antagonism During Cardiopulmonary Bypass PHASE2/PHASE3COMPLETED
Berinert P Study of Subcutaneous Versus Intravenous Administration PHASE3COMPLETED
Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19 PHASE2/PHASE3UNKNOWN
Clinical Trial Using Humira in Netherton Syndrome PHASE2COMPLETED
A Pilot Study of Use of Calcium Channel Blocker to Decrease Inflammation and Pain in Hereditary Pancreatitis PHASE1/PHASE2COMPLETED
Investigation the Effect of Montelukast in COVID-19 PHASE2UNKNOWN
Single Dose Administration of Alpha-1 Anti-Trypsin for the Amelioration of Organ Injury in Patients Undergoing Cardiac Surgery PHASE1/PHASE2UNKNOWN
Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients PHASE2WITHDRAWN
Atorvastatin as Adjunctive Therapy in COVID-19 PHASE2UNKNOWN
Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications PHASE1UNKNOWN
Effects of Topical SLPI on Skin Wounds PHASE1COMPLETED
Gene Therapy for Netherton Syndrome PHASE1UNKNOWN
Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) EARLY_PHASE1UNKNOWN
Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD) nanCOMPLETED
Acute Pancreatitis Targets (APT) Study nanCOMPLETED
Association of Circulating ACE2 Levels With COVID-19 nanCOMPLETED
Belgian Antithrombin Deficiency Registry nanNOT_YET_RECRUITING
Impact of the Genetic Polymorphism on COVID-19 in Egypt nanUNKNOWN
Angiotensin-converting Enzyme 2 (ACE2) Expression in Tonsils and Adenoids nanWITHDRAWN
Influence of Genetic Polymorphisms on Ventricular Structure and Function in Patients With Single Ventricle Anatomy nanCOMPLETED
Cardiac Injury in COVID-19: a Pathology Study nanUNKNOWN
Osteopathic Manipulative Therapy Effects on Post-Acute Sequelae of COVID-19 (PASC) or Long COVID nanRECRUITING
Human Epididymis Protein 4 in Endometrial Carcinoma nanCOMPLETED
Disorders of the Acute Phase Response Following Trauma and Invasive Surgery nanENROLLING_BY_INVITATION
Treatment of Angiotensin Peptide (1-7) for COVID-19 nanCOMPLETED
Nasal Epithelial Genetic and Single Cell RNA COVID-19 Study nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a SPINT2 binder may also engage these)

ProteinNameSimilarity
B2BS84 — 0.999 B2BS84 →
Q9R097 — 0.999 Q9R097 →
Q9WU03 — 0.998 Q9WU03 →
Q8TEU8 — 0.992 Q8TEU8 →
Q08E66 — 0.991 Q08E66 →
P04815 — 0.990 P04815 →
P98154 — 0.990 P98154 →
Q7TQN3 — 0.990 Q7TQN3 →
Q96FE7 — 0.990 Q96FE7 →
Q7YRQ8 — 0.989 Q7YRQ8 →
P00974 — 0.989 P00974 →
O43278 — 0.989 O43278 →
O54819 — 0.988 O54819 →
Q5RCS3 — 0.988 Q5RCS3 →
Q56A20 — 0.987 Q56A20 →
W4VSH9 — 0.987 W4VSH9 →
P00992 — 0.987 P00992 →
Q7TMJ8 — 0.987 Q7TMJ8 →
Q96PD2 — 0.986 Q96PD2 →
TFPI2 Tissue factor pathway inhibitor 2 0.986 landscape →
Q9DC11 — 0.986 Q9DC11 →
P98153 — 0.986 P98153 →
P35546 — 0.986 P35546 →
Q8R0S6 — 0.985 Q8R0S6 →
I2G9B4 — 0.985 I2G9B4 →
E5AJX3 — 0.985 E5AJX3 →
A8Y7N8 — 0.985 A8Y7N8 →
Q28864 — 0.985 Q28864 →
Q5FVR3 — 0.985 Q5FVR3 →
H2CYP1 — 0.985 H2CYP1 →